MARKED VERSION OF AMENDED CLAIMS - 33827-US-009

2. Compounds of the formula I according to [Claim] claim 1, in which

A denoted a benzo ring,

X^1 denotes O, and

R^1 denotes hydrogen.

3. Compounds of the formula I according to claim 1 [Claim 1 or 2], in which

B denotes phenyl, cyclohexyl, piperidine, pyridine, pyrimidine, pyrrole, pyrazole, thiphene, furan, oxazole, naphthalene, piperazine, quinoline, pyrazine or indole, each of which can be substituted by one R^4 or at most 2 R^5.

4. Compounds of the formula I according to claim 1 [at least one of Claims 1 to 3], in which

L denotes a carbon chain which has from 1 to 8 C atoms and which contains at least one triple bond, where the carbon atoms of the chain can be substituted by one or two R^4 radicals and at most two different or identical R^5 radicals,

v denotes 1, and

w denotes 0 or 1.

5. Compounds of the formula I according to claim 1 [at least one of Claims 1 to 4], in which

R^4 denotes $D_{0,1}$-$F^1_{0,1}$-G^2-G^3, where G^3 denotes hydrogen,

D denotes O or NR^{43}, where R^{43} denotes hydrogen or C_1-C_3-alkyl, and

F^1 denotes C_2-C_4-alkyl.

6. Compounds of the formula I according to claim 1 [at least one of Claims 1 to 4], in which

R^4 denotes G^1-F^1_0 ,-G^2-G^3, where G^3 denotes hydrogen, and

F^1 denotes C_1-C_2-alkyl.

7. Compounds of the formula I according to [Claim] claim 6, in which

G^1 denotes imidazole or pyrrole, where the pyrrole can in each case be substituted by at most three different or identical R^5 radicals, and

F^1 denotes C_1-C_2-alkyl.

8. Pharmaceutical composition which comprises at least one compound according to claim 1 [one of Claims 1 to 7] and also at least one customary carrier and/or auxiliary substance.

9. Use of a compound of formula I according to claim 1 [one of Claims 1 to 7] for producing a pharmaceutical for the prophylaxis and/or treatment of neurodegenerative diseases, neuronal damage or damage due to ischaemias, for treating microinfractions, for treating in association with a revascularization of critically stenosed coronary arteries or critically stenosed peripheral arteries, for treating acute myocardial infraction and damage during and after its medicinal or mechanical lysis, for treating tumours and their metastases, and for treating sepsis, multiorgan failure, immunological diseases, diabetes mellitus and viral infections.

MARKED VERSION OF AMENDED CLAIMS - 33827-US-009

10. Process for the prophylaxis and/or treatment of neurodegenerative diseases, neuronal damage or damage due to ischaemias, for treating microinfarctions, for treating in association with a revascularization of critically stenosed coronary arteries or critically stenosed peripheral arteries, for treating acute myocardial infraction and damage during and after its medicinal or mechanical lysis, for treating tumours and their metastases, and for treating sepsis, multiorgan failure, immunological diseases, diabetes mellitus and viral infections by administration of an effective quantity of at leasts one compound of the formula I according to claim 1 [one of Claims 1 to 7].

11. Process for producing a compound according to claim 1 [one of Claims 1 to 7], which comprises condensing an aldehyde of the formula II with a diamine of the formula III:



(II)



(III)

where the symbols in the formulae II and III have the same meaning as in claim [Claim] 1.

12. Process according to claim [Claim] 11, where the diamine of the formula III is

obtained by reacting a substituted nitrobenzoic ester of the formula IV with a diamine of the formula V, in a polar solvent and in the presence of a base, and subsequently hydrogenating:



. (IV)



(V)

where the symbols in the formulae IV and V have the same meaning as in Claim 1 and R^2 denotes branched or unbranched, saturated or unsaturated C_1-C_6-alkyl.